Pfizer's breast cancer compound wins FDA's Breakthrough Therapy designation
 

Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration for the potential treatment of patients with breast cancer.

More...